Skip Navigation

Radiation and Nuclear Countermeasures Program

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Program Awardees

Contracts | Grants

Contract Awardees

Medical Countermeasures Against Radiological Threats: Product Development Support Services (FY2010)

Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency (FY 2010)

Grant Awardees

Centers for Medical Countermeasures Against Radiation (CMCR) (FY 2010)

2010 CMCR Individual Project Descriptions (PDF)

Centers for Medical Countermeasures Against Radiation (CMCR) (FY 2005)

2005 CMCR Individual Project Descriptions (PDF)

Protecting the Immune System Against Radiation (FY 2005)

Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies (FY 2006)

Medical Countermeasures to Restore Gastrointestinal Function after Radiation Exposure: Project Bioshield (RC1) (FY 2007)

Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1) (FY 2008)

BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Cutaneous Injury: Project Bioshield (RC1) (FY 2008)

BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Lung Injury: Project Bioshield (RC1) (FY 2008 - FY 2010)

Mechanisms, Diagnosis, and Treatment of Radiation Injury from a Nuclear Accident or Terrorist Attack (R01) (FY 2008

Radiation Combined Injury: Radiation Exposure in Combination with Burn, Wound, Trauma, or Infection (Phased Innovation Award [R21/R33] (FY 2008)

Grand Opportunities "GO" Grant Awards (FY 2009 - FY 2010)

Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Injuries (R01) (FY 2012)

Development of Medical Countermeasures for Post-Exposure Mitigation/Treatment of Injuries Resulting from a Radiation/Nuclear Incident (U01) (FY 2013)

Intestinal Stem Cell Consortium - ISCC (FY 2009)

Co-funded between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the NIAID, the mission of this consortium of U01 awards is to "…advance the understanding of intestinal epithelial stem cell biology during development, homeostasis, regeneration and disease. The immediate goals of the ISCC are to isolate, characterize, culture and validate populations of intestinal stem cells; answer major questions in stem cell biology of the intestinal epithelium; and accelerate research by making information and resources available to the research community. Long-term goals include: 1) laying the ground work for therapeutic manipulation of the intestinal epithelium 2) contributing to the greater understanding of stem cell biology through knowledge of the intestine as a model stem cell-driven system."

  • Stanford University
    Calvin Kuo
    In Vivo and In Vitro Characterization of BMI1+ Intestinal Stem Cells
  • University of Pittsburgh
    Jian Yu
    Intestinal Stem Cell Survival and Renewal Coordinately Regulated by PUMA and p21
  • University of Oklahoma
    Courtney Houchen
    Isolation and Characterization of Intestinal Stem Cells Using Novel Markers
  • University of California, Los Angeles
    Martin Martin, James Dunn, Matthias Stelzner (multiple PI)
  • University of North Carolina, Chapel Hill
    Susan Henning
    Collaborative Approaches to the Study of Intestinal Epithelial Stem Cells
  • Stowers Institute
    Linheng Li
    Isolation and Characterization of Intestinal Stem Cells
  • University of Pennsylvania
    Anil Rustgi & John Lynch (multiple PI)
    The Intestinal Stem Cell Niche
  • Oregon Health Sciences University
    Melissa Wong
    Characterization of Intestinal Stem Cells
  • Beckman Research Institute/City of Hope
    Joyce Niland
    Intestinal Stem Cell Consortium Coordinating Center

Armed Forces Radiobiology Research Institute

Program Background

Established in 2005, the Inter-Agency Agreement between the NIAID and the Armed Forces Radiobiology Research Institute (AFRRI) funds research in several areas related to the challenges encountered following radiological or nuclear events. These include: 1) Screen countermeasures to prevent, mitigate/ treat radiation injuries; 2) Automation of dicentric assay; 3) Develop animal model, study mechanism and screen countermeasures to mitigate/treat radiation combined injury; 4) Develop animal model, study mechanism and screen countermeasures to mitigate/treat gamma/neutron mixed field injury; 5) Develop Gottingen Minipig as a Model for Acute Radiation Syndrome.

Research Highlights

NIAID-funded AFRRI’s screening program has performed toxicity studies, dose optimization, time optimization for post exposure, optimum route of administration and efficacy of post exposure (24 hr and beyond) administration of 55 single drugs and 3 combinations on survival in CD2F1 male mice at LD90/30 and LD70/30 doses. One of the promising drugs is being evaluated for post- exposure efficacy in non-human primate model. NIAID-funded work at AFFRI has automated dicentric sample processing and scoring with a throughput of approximately 1000 samples per day. In addition, AFRRI has developed and characterized rodent model for radiation+wound and radiation+burn combined injury as well as neutron (65%) + gamma (35%) mixed field injury, and efficacy evaluation of several potential countermeasures in these animal models is on-going. Also, AFRRI has developed and characterized Gottingen Minipig as a model for acute radiation syndrome.

National Cancer Institute

Program Background

The National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI) are cooperating on specific research ranging from identification, characterization and validation of safe and effective radiation/nuclear medical countermeasures, development of biology-based diagnostic assays or biomarkers to assess cellular and tissue damage following exposure to ionizing radiation and addressing other scientific areas with strong programmatic relevance, such as radiation epidemiology and radionuclide decorporation.

The following principal investigators within intramural NCI have projects being funded by this intramural opportunity within the NIAID Radiation/Nuclear Countermeasures Program:

Division of Cancer Epidemiology & Genetics

Center for Cancer Research

Research Highlights

Scientific accomplishments for this program include:

  • Finding of a large bystander effect in 3-dimensional skin and airway radiation exposure models. This has implications for effects of partial body irradiations or inhomogeneous exposures.
  • Demonstration of a clear separation in metabolomic signatures between sham and irradiated in vitro samples, with little variation between sham-irradiated cells, and identification of several candidate metabolomic markers for radiation exposure.
  • Analysis of I-131 biokinetic data from 140 patients treated with I-131 for hyperthyroid, EPR analysis of 103 teeth from Semipalatinsk, Kazakhstan populations exposed to radiation, and testing of a novel biodosimetry system based on optically stimulated luminescence (OSL).
  • Synthesis of 8 nitroxide analogs and irradiation of 1,275 mice (2 strains) in order to evaluate the efficacy of Tempol food in minimizing radiation-induced carcinogenesis.

National Institute on Aging

Program Background

The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute on Aging (NIA) are cooperating on specific research and development projects to benefit both Institutes’ goals of advancing the study of immunesenescence from the natural process of aging and radiation exposure, and its amelioration in prevention and intervention therapies. Awarded in September, 2009, the following laboratories within intramural NIA are being funded:

Research Highlights

These research projects, funded at the end of FY09, focus on how ionizing radiation and natural aging affect a person’s ability to respond to vaccination and the ability of the immune system to respond to vaccination and cause inflammation which is a hallmark of immune aging.

Last Updated December 20, 2012